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Johana M Isaza-Correa, Zheng Liang, Anke van den Berg, Arjan Diepstra and Lydia Visser*Abstract
Toll-like receptors (TLRs) are important players in B-cell activation, maturation and memory and may be involved in
the pathogenesis of B-cell lymphomas. Accumulating studies show differential expression in this heterogeneous
group of cancers. Stimulation with TLR specific ligands, or agonists of their ligands, leads to aberrant responses in the
malignant B-cells. According to current data, TLRs can be implicated in malignant transformation, tumor progression and
immune evasion processes. Most of the studies focused on multiple myeloma and chronic lymphocytic leukemia, but in
the last decade the putative role of TLRs in other types of B-cell lymphomas has gained much interest. The aim of this
review is to discuss recent findings on the role of TLRs in normal B cell functioning and their role in the pathogenesis of
B-cell malignancies.Toll-like receptors (TLRs) are essential receptors of the
innate immune system and key regulators of the
acquired immune system. Ten proteins (TLR1–10) have
been identified in humans [1,2], each of them with a
particular subcellular localization depending on the
specific pathogen-associated molecular patterns (PAMPs)
or damage-associated molecular patterns (DAMPs) they
recognize (Table 1). TLR2 forms functional heterodimers
with either TLR1 or TLR6. These heterodimers together
with TLR4 and TLR5 are expressed on the cell membrane,
whereas TLR3, TLR7, TLR8 and TLR9 are located in
endosomes. TLRs induce pro-inflammatory molecules
but, they are also implicated in proliferation, survival, and
tissue repair [3].
TLRs are pattern recognition receptors structurally
characterized by extracellular leucine rich repeats,
and transmembrane and intracellular Toll/Interleukin-1
receptor (TIR) domains [1,3]. The extracellular domain
interacts directly with PAMPs or DAMPs, triggering
the downstream signaling through the TIR domain
[1]. In mammals, four different types of signaling
adaptor proteins can be recruited by the TIR domain:
Myeloid differentiation primary-response protein 88
(MyD88), TIR-domain-containing adaptor protein inducing
IFNβ (TRIF), TRIF-related adaptor molecule (TRAM),* Correspondence: l.visser@umcg.nl
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article, unless otherwise stated.and TIR-domain-containing adaptor protein (TIRAP)
(Figure 1). The MyD88 signaling cascade is essential for
TLR2, TLR4, TLR5, TLR7, TLR8 and TLR9. TIRAP
activation is MyD88-dependent and is associated with
TLR2 and TLR4. TRIF acts independently of MyD88 in
signal transduction following TLR3 and TLR4 activation.
TRAM mediates TLR4 signaling in a MyD88-independent/
TRIF-dependent way [1]. The adaptor proteins serve
as a scaffold for the recruitment of IL-1R-associated
kinases (IRAK) 1, 2, 4 and M and TAB2 and TNF-
receptor-associated factor 6 (TRAF6) which eventually
leads to nuclear translocation of Nuclear factor kappa-B
(NF-kB) [1,3] (Figure 1). Other transcription factors
that can be activated are activator protein 1 (AP-1)
and interferon regulatory factor 3 (IRF3) [1].
The contribution of TLRs to B-cell lymphoma
pathogenesis has gained more interest in recent years
[2,4], but it is not completely understood. This review
summarizes the current knowledge on the expression
of TLRs in normal B-cells and in B-cell malignancies
and discusses how TLRs can contribute to onset and
progression of these malignancies.Expression and function of TLRs in normal B-cells
Although expression of TLRs in normal B-cells is
interesting, what happens in B-cells when they are
triggered or the role they play in B-cell maturation and
differentiation is more important.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Toll-like receptors (TLRs) and their DAMPs and PAMPs ligands
DAMPS (endogenous) PAMPs (exogenous)
Ligand Ligand Origin
TLR1 Tri-acylated Lipopeptides Bacteria and Mycobacteria
Soluble factors Neisseria meningitidis
TLR2 HSP60, HSP70, HSP96 Lipoprotein/lipopeptides Various pathogens
HMGB1 Peptidoglycan Gram + bacteria
Hyaluronic acid Lipoteichoic acid Gram + bacteria
Lipoarabinomannam Mycobacteria




Atypical-LPS Leptospira interrogans and Porphyromonas gingivalis
Zymosan Fungi
TLR3 dsRNA, mRNA dsRNA Viruses
TLR4 HSP22, HSP60, HSP70, LPS Gram- bacteria
HSP96 HSP60 Chlamydia pneumonia
HMGB1β-defensin 2 Fusion protein Respiratory syncytial virus
fibronectin Envelope proteins Mouse mammary tumor virus




TLR5 Flagellin Gram + or Gram- bacteria
TLR6 Di-acylated lipopeptides Mycoplasma
Lipoteichoic acid Gram + bacteria
Zymosan Fungi
Phenol-soluble modulin Staphylococcus epidermis
Heat-liable soluble factor Group B streptococcus
TLR7 Endogenous RNA ssRNA Viruses
TLR8 Endogenous RNA ssRNA Viruses
TLR9 Endogenous DNA Unmethylated CpG motifs Bacteria and viruses
Hemozoin Plasmodium
TLR10 Unknown Unknown
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A number of studies investigated expression of TLRs
in B-cell subsets isolated from peripheral blood
mononuclear cells (PBMC) or tonsil. PBMC derived
B-cells express TLR1, TLR6, TLR7, TLR9 and TLR10 [5].
Analysis of peripheral naïve and memory subsets indicates
that only TLR1, TLR7 and TLR9 are expressed at low
levels in naïve B-cells, while memory B-cells express
high levels of TLR6, TLR7, TLR9 and TLR10 [6].
Tonsillar B-cells express less TLR7 than peripheral B-cells,
but show higher TLR9 levels [7]. Bone marrow plasmacells express TLR1, TLR8 and TLR9 in a small subset of
healthy controls [8].
Triggering of TLRs in B-cells
Triggering of resting or naïve B-cells through the B-cell
receptor (BCR), CD40 or CpG oligodesoxynucleotides
(CpG) induces a quick upregulation of TLR7, TLR9
and TLR10 [6,9]. Triggering of TLR9 on PBMC derived
B-cells with CpG induces its downregulation and in
addition leads to an upregulation of TLR7 [5]. Bernasconi
[6] hypothesized that low or null expression of TLRs in
Figure 1 Signaling pathway of toll-like receptors (TLRs). After recognition of the ligand by the extracellular domain of TLRs, adaptor proteins
are recruited to the TIR domain and initiate intracellular signaling. Four types of adaptor proteins have been identified in mammals: MyD88, TRIF,
TRAM, and TIRAP. The recruitment of IRAK and TRAF6 to the adaptor proteins leads to nuclear translocation of NF-kB. TRAF6 can also activate
MAPK kinases (MKK) leading to the activation of transcription factor AP-1. This pathway is common to all the TLRs, except for TLR3 which uses
TANK-binding kinase 1 (TBK1) and results in the activation of IRF3.
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activation. The high and diverse expression of TLRs in
memory B-cells on the other hand, might facilitate continu-
ous antibody production. Production of type I interferon
(IFN) by plasmacytoid dendritic cells (pDCs) in response to
infections positively modulates the expression of TLR7 but
not of other TLRs in naïve B-cells [10].
Triggering of TLR1/TLR2, TLR7 and TLR9 in B-cells
results in the upregulation of several B-cell activation
markers, including HLA-DR, CD25, CD80 and CD86, as
well as the production of several cytokines and chemokines
[7,11] (Figure 2). Cytokine production levels were higher in
memory B-cells as compared to naïve B-cells, whereas
chemokines are produced at similar levels [11].
The role of TLRs in B-cell maturation and differentiation
Several studies showed that TLRs are involved in the
formation of germinal centers (GC) (Figure 2). Stimulationof TLR2+ human B-cells, a small subpopulation found
in blood or spleen, causes a GC like differentiation with
upregulation of CD77 and production of CXCL13, CXCL8
and IL-6 [12]. In TLR7 deficient mice no GC B-cells are
formed after immunization with Friend Virus [13],
whereas in IL-21Rko mice, GC formation is dependent on
the presence of TLR7 ligands [14].
Several studies demonstrate a crucial role of TLR
triggering in the induction of class switch recombination
(CSR). Stimulation of TLR4 with LPS can induce IgG2b
CSR, while addition of IL-4 blocks this process [15]. CpG
stimulation of TLR9 in the presence of MYD88, induces
CSR to IgG2a, IgG2b and IgG3 in murine B-cells
[16]. In human naïve (CD19+ CD27- IgG/A- ABCB1+)
B-cells, TLR9 stimulation with CpG was required for
CSR to IgG and IgA, in addition to BCR ligation and
T-cell help [17]. T-cell independent stimulation of TLR9
with CpG in combination with IL-10 treatment of naïve
Figure 2 The role of TLRs in B-cell activation and differentiation. TLR ligation constitutes one of the three activation signals of naïve-B cells
next to BCR triggering and T-cell interaction through CD40. The latter two signals upregulate the expression of TLRs, which subsequently interact
with their respective ligands to activate naïve B-cells completely. Activation through TLRs enhances expression of membrane molecules and the
production of cytokines and chemokines. It also induces proliferation, somatic hypermutation and class switch recombination. After their first
encounter with the ligand and consequent maturation, germinal center cells can further transform into antibody-secreting plasma cells or memory
B cells. TLR signaling has been proven to increase antibody secretion and participates in the maintenance of serological memory.
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deaminase (AID) and the subsequent CSR to IgG1, IgG2,
and IgG3 [18]. Upper respiratory mucosal B-cells can be
stimulated with dsRNA via TLR3 and TRIF, to activate
NF-κB and induce expression of AID and CSR to IgG
and IgA [19]. BCR independent activation of murine
resting B-cells via TLR2 and CD40 causes proliferation
and differentiation to marginal zone precursor cells that
have upregulated AID expression [20].
Somatically mutated memory B-cells can be generated
from immature transitional B-cells upon CpG treatment.
Most of the somatic hypermutations were observed in
B cells containing VH1, VH4 and VH6 gene segments
[21]. This study indicates that somatic hypermutation
is dependent on or can be induced by TLR triggering.
Differentiation to plasma cells and the production of
antibodies are two processes in which TLRs also play an
important role (Figure 2). Several immunization studies
in mice show that TLRs are essential for the production of
antibodies. T-cell dependent immunizations in MyD88 KO
mice do not lead to the production of antibodies, while
triggering of TLR4 during the immunization procedure ofwild type mice induces a significant increase in antibody
titers [22]. Stimulation of TLR4 and TLR7 signifi-
cantly enhanced antibody titers upon immunization
[23]. Immunization with CpG linked to the protein
antigen enhances B-cell proliferation and plasma cell
differentiation [24]. For induction of an anti-viral response,
MYD88 expression in B-cells was essential [13,25].
Naïve B-cells stimulated by CpG start proliferating
and differentiate to IgM producing plasma cells with
increased surface expression of molecules involved in
antigen presentation such as HLA-DR, CD40 and CD80.
These cells indeed have an increased potential to activate
allogeneic T-cells [26]. Cord blood transitional B-cells
express TLR9 and respond to CpG by expression of AID
and BLIMP-1 and produce anti-pneumococcal antibodies
as a first line defense at birth [27]. CpG stimulation of
TLR9 positive IgM memory B cells drives differentiation to
plasma cells that produce IgM antibodies to Streptococcus
pneumoniae [27].
In summary, multiple studies show participation of
TLRs in adaptive immunity, including modulation of the
activation of B- and T-cells. In B-cells TLRs have been
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complete activation [17], along with BCR triggering and
interaction with T-cells. Additionally, it has been shown
that TLRs are involved in B-cell maturation by CSR,
somatic hypermutation, induction and maintenance of
GC and B-cell memory, differentiation to plasma cells
and the production of antibodies. Considering the amount
of evidence supporting TLR-MyD88 involvement in
acquired immune responses mediated by B-cells, it is
likely that they are involved in the pathogenesis of B-cell
malignancies.
TLR expression in B-cell malignancies
B-cell malignancies are classified based on the resemblance
of the tumor cells to specific maturation stages of normal
B-cells, e.g. the normal counter part of follicular lymphoma
(FL), Burkitt lymphoma (BL) and diffuse large B-cell
lymphoma (DLBCL) are related to germinal center B-cells,
while multiple myeloma (MM) is a plasma cell malignancy.
Expression in multiple myeloma
TLR1, TLR2, TLR3, TLR4, TLR7, TLR8, and TLR9 have
been reported to be expressed in MM derived cell lines.
Of these TLR1, TLR4, TLR7, and TLR9 are expressed
most commonly [8,28]. Analysis of tumor cells from
sorted bone marrow mononuclear cells of MM patients
showed high TLR2, TLR4 and TLR9 mRNA levels and
these findings were consistent with the high protein expres-
sion of TLR4 and TLR9 when analyzed by flowcytometry
[29]. Overall, the expression of TLR4 and TLR9 is
consistently reported in MM cell lines or primary cells.
Expression in chronic lymphocytic leukemia (CLL)
TLR1, TLR2, TLR6, TLR7, TLR9 and TLR10 were
expressed in CLL, while the other TLRs were low or
negative [30-32].
Expression in other B-cell malignancies
For other B-cell lymphoma types, studies on TLR
expression are limited. In acute lymphoblastic leukemia
(ALL) cell lines, TLR1, TLR2, TLR3, TLR4, TLR6 and
TLR7 are expressed albeit at variable levels [33]. In bone
marrow of ALL patients with >90% blasts TLR2
mRNA can be detected in the majority of the samples
[33]. BL cell lines express TLR7 and TLR9 [34]. Mucosa
associated lymphoid tissue (MALT) lymphoma show
strong expression of TLR4 and weak expression of TLR5
[35]. In mantle cell lymphoma (MCL), TLR1, TLR4, TLR7,
TLR9 and TLR10 exhibit significant mRNA levels,
whereas TLR2, TLR3, TLR5 and TLR8 are negative [36].
A significant expression of TLR2 and TLR8 at both the
protein and mRNA level was found in DLBCL [37]. In
comparison to reactive lymph node, TLR2 levels were
high in DLBCL and TLR5 low in follicular lymphoma(FL). TLR3, TLR6, TLR7 and TLR9 expression levels
were similar in DLBCL, FL and peripheral T cell
lymphoma [37].
Polymorphisms in TLRs have been shown to increase
the risk of non-Hodgkin lymphoma [38], as well as in
Hodgkin lymphoma [39-41].
Thus, it is evident that B-cell malignancies display a
wide range of TLR expression patterns. Nevertheless, it
remains to be elucidated if their expression resembles a
normal B-cell phenotype or if it is a consequence of the
malignant transformation.
Potential role of TLRs in B-cell malignancies
The survival and proliferative mechanisms used by
malignant cells usually includes aberrant activation of
signaling and regulatory pathways that are also used
in their normal counterparts. Three possible pathogenic
mechanisms can be anticipated for the TLRs which will be
discussed below (See Figure 3).
Role of TLRs in the transformation of normal B-cells into
malignant B-cells
One of the main indications that TLR are involved in
the pathogenesis of B-cell malignancies comes from
studies focusing on its adaptor protein MyD88.
Knockdown of MyD88 in activated B cell type (ABC)
DLBCL cell lines causes a marked decrease in proliferation,
this effect was shown to be dependent on the presence of
oncogenic mutations [42]. Specific oncogenic mutations in
the Toll/IL-1 receptor (TIR) domain of MyD88 are
found in 91% of lymphoplasmacytic lymphomas [43],
29% of ABC DLBCL, 9% of gastric MALT lymphomas
[42], 13% of splenic marginal zone lymphomas (SMZL)
[44], 2.9% of CLL cases and 5.6% of IgH-mutated CLL
cases [45].
NF-κB is constitutively activated in various lymphoma
subtypes and presents an important pathway to evade
cell death. This is demonstrated by the frequent
occurrence of somatic mutations in NF-κB related
genes in mature B-cell lymphomas [46]. As NF-κB
can be activated via triggering of the TLRs, this might
provide a potential mechanism to avoid apoptosis and
increase their proliferation rates. Consistent with this,
triggering of TLR4 and TLR9 in MM resulted in nuclear
translocation of NF-kB, and enhanced cell growth and
IL-6 production [29]. In a similar way, ligation of
TLR1/2 and TLR6/2 increased tumor cell survival in
CLL by triggering NF-κB signaling [32].
Several B-cell lymphomas have been associated with
viral or bacterial infections [47-50]. This led to the
speculation that acute and sustained infections trigger
malignant B-cell transformation via activation and
induction of a prolonged proliferative state, favoring
accumulation of genetic aberrations. The strongest
Figure 3 Possible roles of TLRs in the pathogenesis of human B-cell lymphomas. There are three possible mechanisms by which TLRs favor
the pathogenesis of B cell malignancies. First, they can indirectly induce B-cell transformation by increasing the probability of mutations and
double stranded DNA breaks after activation of naive B-cells or by favoring a pro-inflammatory microenvironment that increases the chance of
mutations. Secondly, TLRs can direct the selection of a malignant clone by increasing proliferation and inhibiting apoptosis through the specific
activation of NF-κB. Finally, malignant B-cell can modulate the immune response through stimulation of TLRs in two ways possibly depending on the
cell type: The-pro tumor response favoring the increase of suppressor cells (like Tregs), and the decrease of a cytotoxic response (by downregulating
Th1, Th17 and CTL) or an anti-tumor response by inreasing immunogenicity and increasing the sensitivity to CTLs and upregulating Th1.
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and prolonged remission of gastric MALT lymphoma
after treatment of Helicobacter (H.) pylori infections
[51-53]. Interestingly, there is a correlation between
infection and TLR expression pattern reported for
specific lymphoma subtypes. MALT lymphomas
express TLR4 [35] which recognizes LPS derived from
Gram-negative bacteria like H. pylori [48]. BL andDLBCL express TLR7, TLR8 and/or TLR9 [34,37], which
mainly recognize single-stranded RNA or unmethylated
CpG motifs from viruses. These lymphoma subtypes,
although for DLBCL in only a small subpopulation of
patients, have been associated with viruses like
Epstein-Barr, Human immunodeficiency virus and
HCV [47,49,50]. As TLRs have been shown to affect
somatic hypermutation and class switch recombination
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also facilitates non-Ig somatic aberrations that leads or
contributes to the malignant transformation of germinal
center B-cells.
In summary, the above mentioned studies provide
evidence, although still mostly speculative and future
analyses are required, for a possible role of TLRs in
the malignant transformation via continuous TLR
triggering following chronic infections or via induction
of a cellular conditions that is prone to somatic mutations
or DNA breaks.
TLRs in proliferation of malignant B-cells and lymphoma
progression
Several studies showed induction of proliferation of
malignant B-cells upon TLR triggering. Stimulation of
TLR9 by CpG in 31 B-cell lymphoma samples strongly
induced proliferation in CLL, revealed intermediate
effects in MZL, CLL/SLL, FL and DLBCL and no effect
in MCL and ALL [30,33]. ALL cells also did not respond
to stimulation of TLR2 and TLR7 [33]. TLR4 triggering
in MCL did show enhanced proliferation [36]. In CLL
stimulation of TLR9 revealed more proliferation in
unmutated compared to mutated IgH cases. Mutated
cases showed a G1/S cell cycle arrest and increased
number of apoptotic cells [54]. In MM cells, ligands
for TLR1, TLR2, TLR4, TLR5, TLR6, TLR7 and TLR8
enhanced IL-6 dependent proliferation [8,28]. Activa-
tion of TLR7 and TLR9 protected MM cells from
serum-deprivation or dexamethasone induced apoptosis
[28]. One of the main contributors to the enhanced
proliferation is probably achieved via the induction of
NF-κB, which also protects the cells from apoptosis
(see above).
Together, these findings indicate that aberrant TLR
activation in B-cell lymphoma may contribute to their
proliferative potential and protect cells from apoptosis.
TLRs in immune modulation
TLRs have been proposed to contribute to the pathogenesis
of B-cell malignancy as modulators of the immune system.
Putative mechanisms involve modulation of pro- and
anti- inflammatory cytokines and costimulatory mole-
cules, induction of regulatory cells and alteration of
T-cell function.
Triggering of TLR7 and/or TLR9 enhanced expression
of co-stimulatory molecules, cytokines and/or chemokines
in BL, CLL and ALL [30,31,34,55,56]. This indicates
that the tumor cells become more immunogenic. Indeed,
activation of TLR7 increases the sensitivity of CLL cells to
cytotoxic T-cells [31,57]. LPS pre-treated primary MCL
cells are able to resist killing by allogeneic cytotoxic
T-cells by producing IL-10 and VEGF [36]. Triggering
of ALL cells with the TLR9-ligand, failed to promoteT-cell proliferation by primary ALL cells, but turned
the T-cell cytokine profile towards Th1 by upregulating
IFN-γ production of T-cells [57]. TLR2-stimulated ALL cell
lines also enhanced expression of co-stimulatory markers
and IFN-γ, but failed to induce T-cell proliferation [33]. In
the normal B-cell response, enhancement of IL-6, IL-10, or
IFN-γ in response to TLR stimulation has been correlated
to immunosuppressive functions. IL-10 production by
B-cells after TLR4 or TLR9 triggering suppresses Th1 and
Th17 cells [58] and after TLR2 stimulation induces IL-10
producing T regulatory (Treg) cells [59]. Patients with
MM or lymphomas, such as FL, DLBCL and primary
mediastinal B-cell lymphoma, frequently have high num-
bers of Treg cells in the microenvironment [60,61]. In
addition, the in vivo and in vitro generation of Treg cells
by B-cells was recently reported to be MyD88-dependent
indicating another link with TLR stimulation [59].
Overall, there is clear evidence that supports a putative
role of the TLRs in the modulation of the immune
response and microenvironment in B-cell malignancies.
The presence and activation of TLRs induces different
mechanisms depending on the lymphoma subtype, the
stimulated TLR and the microenvironment. TLR stimula-
tion can favor proliferation of malignant B-cells by facili-
tating immune evasion through Treg induction and
production of immunosuppressive cytokines. In contrast,
in some situations, TLRs can stimulate resolution of
the tumor by encouraging a cellular-mediated immune
response.
Therapeutic perspectives
A main question to be addressed is: what are the effects
of TLR agonists in vivo? In a mouse model for ALL,
treatment with CpG oligonucleotides gave long term
protection from ALL, by inducing a Th1 response [62,63].
Topical administration of Imiquimod, the ligand for
TLR7, resolves skin manifestations in CLL patients
and increased expression of co-stimulatory molecules on
leukemic tumor cells [64]. A phase I study of TLR9
stimulation combined with rituximab in non-Hodgkin
lymphoma showed no toxicity, induction of interferon
and interferon inducible genes and an overall response
rate of 32% (6/19) [65]. The phase II follow up study in
relapsed and refractory FL patients, revealed enhanced
antibody-dependent cell-mediated cytotoxicity in 11/23
patients, and 74% of patients were alive without pro-
gressive disease at day 90 [66]. At least six clinical trials
evaluating agonists for TLR3 (1 Trial), TLR7/8 (2 Trials)
and TLR9 (3 Trials) in B non-Hodgkin lymphomas were
in progress at January of 2008 [67]. Most of these have
been terminated for different reasons, or the results have
not been published yet. A phase I/II trial in CLL with a
TLR7 agonist showed that part of the patients could be
sensitized for vincristine [68], as had also been shown
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agonists has been reported to be low in Phase III studies,
so the number of research groups following this direction
has decreased [67].
Conclusion
TLRs have been suggested as promoters of malignant
transformation, tumor cell maintenance and progression
in B-cell malignancies. The TLR expression patterns
are diverse, not completely known yet for each B-cell
malignancy, and could be normal for the B-cell phenotype
or a consequence of transformation. TLR stimulation
induced different effects in B-cell malignancies due to
specific aberrations in the tumor cells or by differences in
the tumor microenvironment. Despite these uncertainties,
it is very likely that TLRs participate in the development
and survival of malignant B cells.
There is a strong correlation between chronic infections
and the development of some specific types of B-cell
lymphoma. In these subtypes, it is likely that TLRs are
directly involved in malignant transformation. In other
B-cell malignancies, such as MM and CLL, TLRs appear
to participate in immune evasion and tumor progression.
It is evident that extreme precaution should be taken
when considering the use of TLR agonists as (adjuvant)
therapy in B-cell malignancies, because these agonists
may have tumor-promoting properties.
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